BJ Rimel, MD, Discusses Biggest Takeaways from 2021 SGO Annual Meeting

Video
Conference|Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO)

Rimel, of the Cedars-Sinai Medical Center, focused her attention on the main takeaways to come out from the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

BJ Rimel, MD, of the Cedars-Sinai Medical Center spoke to CancerNetwork® regarding her biggest takeaways when it comes to the data presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Transcription:

The biggest takeaway for the annual meeting for me is the excitement around seeing the perspectives of clinical trials, innovations in office care, [and] innovations in how we approach getting data from patients or about patients to serve them better. I really thought that was an exciting part of the meeting and I’m looking forward to seeing more of it.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content
XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

XTR008 Significantly Extends Progression-Free Survival in SSTR+ GEP-NETs

Sabrina Serani
October 18th 2025
Article

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

Giredestrant Combo Improves Efficacy vs SOC in ER+, HER2- Breast Cancer

Silas Inman
October 18th 2025
Article

Giredestrant plus everolimus doubled the ORR and prolonged the DOR in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Fruquintinib/Sintilimab Shows Promising PFS in Advancing RCC, 1L VEGFR TKI Therapy

Jax DiEugenio
October 18th 2025
Article

Fruquintinib plus sintilimab significantly enhanced PFS in advanced RCC offering a promising second-line treatment option.

Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Pimicotinib Yields Long-Term Response in Tenosynovial Giant Cell Tumor

Chris Ryan
October 18th 2025
Article

Pimicotinib shows promising long-term efficacy and safety for treating tenosynovial giant cell tumor, offering significant patient benefits in a recent trial.